Birth control vending machines, seasonal shots, and the “Snoo”
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning…
Category: Medicine
Moderna reports encouraging results on its mpox vaccine, as outbreaks in Africa spread
The emergence of a second mpox outbreak in which the virus is spreading from person…
Study of gender-affirming care reveals immune system sex differences
Researchers have long known that, in general, women are more susceptible to autoimmune disorders than…
STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
BioMarin’s big day today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance
Novartis is opening a new manufacturing facility in California and expanding an existing production site…
Trying to time your seasonal vaccines just right? There are no easy answers, but here are some factors to consider
With fall coming into view, public health officials across the country are turning to the…
Birth control has become harder to get. New York has some creative solutions
A typical vending machine on a university campus might offer students the usual range of…
Opinion: The Snoo can’t help the people who need it most
When you have a baby, sleep becomes the holy grail. You become convinced that getting…
How race became ubiquitous in medical decision-making tools
It was created with the best intentions: a government policy asking researchers to collect racial…
STAT+: Drug aimed at strengthening neurons to treat Alzheimer’s fails in trial
A dark horse effort to treat Alzheimer’s disease, already marred by a data manipulation scandal,…
STAT+: Greece’s antitrust regulator probes Novartis over practices tied to a pricey eye drug
Greece’s antitrust regulator is investigating allegations that, over a nine-year period, Novartis paid doctors and…
STAT+: Vaxcyte shares boom as one of biotech’s big David vs. Goliath stories heats up
With new vaccine data released Tuesday, Vaxcyte, a San Carlos, Calif.-based firm, emerged as one…
STAT+: Dana-Farber CEO Laurie Glimcher to step down, saying ‘we must look to the next generation’
Laurie H. Glimcher, chief executive of Dana-Farber Cancer Institute, said she would step down next…
STAT+: Pharmalittle: We’re reading about Medicare drug prices, a Sanofi MS pill, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
A STAT Investigation: Embedded Bias
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
STAT+: Recursion presents mixed data on lead AI-derived drug candidate for potentially fatal brain condition
Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that,…
STAT+: European court sides with Illumina, saying regulators overstepped in scrutiny of Grail deal
LONDON — Europe’s top court on Tuesday ruled that regulators overstepped in challenging the DNA…
Explore the clinical tools that use race to steer care
Every day, physicians use clinical algorithms to make decisions about the patients in their exam…
Doctors use problematic race-based algorithms to guide care every day. Why are they so hard to change?
Pediatrician Alexandra Epee-Bounya had had enough. In her 20 years caring for children in Boston,…
STAT+: Diagnosed with cancer, a pharmaceutical executive became a patient advocate and changed drug development. It took decades
Kathy Giusti was diagnosed with multiple myeloma in 1996, when she was a 37-year-old executive…
Why clinicians are reconsidering race-based algorithms
Algorithms are ubiquitous in medicine. They can take the form of a flowchart, a simple…
Opinion: Letting funding for the All of Us research program lapse will cost the U.S. far more than it saves
I was in high school when I first encountered the ruthlessness of the number one…
STAT+: At major cardiology conference, Wegovy’s the word
LONDON — When Europe’s largest cardiology conference opened here this past Friday, one of the…
STAT+: Sanofi says its new pill for multiple sclerosis succeeded in a key trial, boosting its research ambitions
Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a…
STAT+: HCA and UnitedHealth resolve contract disputes in four states hours before deadline
HCA Healthcare and UnitedHealthcare reached agreements just hours before their contracts were scheduled to expire…
Opinion: The alliance between RFK Jr. and Trump all comes down to their health-related worldview
Robert F. Kennedy Jr.’s priorities may seem like a random grab bag of contrarianism, conspiracies,…
STAT+: A ‘tie-breaker’ study of Abbott’s heart clip brings more questions than answers
A study meant to serve as a tie-breaker between two major trials of a heart…
FDA clears updated Covid shots from Novavax, adding a 3rd fall vaccine option
U.S. regulators have cleared a third updated Covid-19 vaccine for this fall, shots made by…
STAT+: Pharmalittle: We’re reading about Wegovy study results, an Alnylam heart drug, and more
And so, another working week will soon draw to a close. Not a moment too…
Monica from ‘Friends’, RFK Jr., and how many ‘r’s are in ‘strawberry’
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
STAT+: Detailed data on Alnylam’s heart drug show substantial benefit, while competition likely awaits
LONDON — An experimental drug from Alnylam Pharmaceuticals substantially cut the risk of death and…
STAT+: Wegovy cut patients’ chances of dying from Covid-19, new analysis shows
LONDON — Novo Nordisk made worldwide headlines last year when a study demonstrated that Wegovy,…
Los Angeles County: the epicenter of urban maternity ward closings
LOS ANGELES — Simone DeRoche, expecting her fourth child in December, had her birth plan…
After decades of anti-vaccine rhetoric, RFK Jr. pivots to chronic diseases — and gets Trump on board
WASHINGTON — Last month, before he called it quits on a presidential run, Robert F….
Opinion: Health care price regulation is undemocratic
The Biden administration recently announced that it will use taxpayer dollars to “stabilize” Medicare Part…
STAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure
Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a…
California, nation’s largest milk producer, discloses possible bird flu outbreaks in three dairy cow herds
On Thursday, the California Department of Food and Agriculture announced it is investigating the possible…
Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy
What’s behind the “great abandonment” in gene therapy R&D? How does a startup spend $213…
Switching asthma inhalers could reduce carbon emissions, says study
Concerns over health care’s carbon footprint typically revolve around issues like overly-air-conditioned hospitals and single-use…
STAT+: Thoughts, takes, and burning biotech questions as the beginning of the end of the year approaches
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
Is the GLP-1 party running down for Hims, and a study for the weekend
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
Genentech is shedding even more employees
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: The weight loss drug shortage is driving patients to Hims. What happens when the shortage ends?
Hims & Hers, one of the largest publicly traded telehealth companies in the country, has…
Opinion: Conversations about improving prenatal care must include transgender and gender diverse birthing people
I dreamed of having children from a young age — so much so that I…
Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats
Eli Lilly garnered widespread praise Tuesday for launching discounted versions of its blockbuster obesity drug…
.jpg)
STAT+: Pharmalittle: We’re reading about Zantac court cases, a Neurocrine schizophrenia pill, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
Hims takes a blow from Lilly’s vial news
Good morning. As a treat for Labor Day weekend, we’re running a deal for STAT+…
STAT+: Neurocrine reports mixed results on schizophrenia therapy in mid-stage trial
Neurocrine Biosciences said Wednesday that the lowest dose of an experimental pill for schizophrenia reduced…